Furosemide

證據等級: L5

預測適應症: 10 個

Furosemide: From Oedema and Hypertension to Malignant Hypertensive Renal Disease

One-Sentence Summary

Furosemide is a well-established loop diuretic, most widely recognised for managing fluid overload and hypertension. The TxGNN model predicts it may also be effective for Malignant Hypertensive Renal Disease, but this specific prediction currently has no supporting clinical trials or published literature — it is a model-only signal.

Quick Overview

Item	Content
Original Indication	Not available in this evidence pack (no ARTG licence text; furosemide is generally recognised as a loop diuretic used for oedema and hypertension)
Predicted New Indication	Malignant Hypertensive Renal Disease
TxGNN Prediction Score	98.03%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on general pharmacological knowledge, furosemide is a loop diuretic that inhibits the Na-K-2Cl (NKCC2) cotransporter in the thick ascending limb of the loop of Henle, producing natriuresis and reduced intravascular volume — an effect long used clinically to manage fluid overload and blood pressure.

Malignant hypertension is frequently accompanied by rapid renal impairment driven by pressure-related vascular injury and volume expansion. Volume control via loop diuretics is a plausible adjunct mechanism in this setting, which may explain why the TxGNN model surfaced this association.

However, this mechanistic plausibility is not yet supported by any identified clinical trial or literature evidence for this specific indication (see below) — the prediction should be treated as a hypothesis-generating signal only, not as evidence of efficacy.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is high (98.03%), but there are zero clinical trials and zero published literature records specifically supporting furosemide’s use in malignant hypertensive renal disease, and furosemide is not currently marketed in Australia (0 ARTG entries) — evidence is insufficient to progress this candidate.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) and DrugBank classification data
TGA/ARTG regulatory status and Product Information (safety, contraindications, DDI)
Targeted literature and preclinical searches specific to malignant hypertensive renal disease
Note: other predicted indications in this evidence pack for furosemide — e.g., chronic pulmonary heart disease (22 trials, 20 publications) and chronic kidney disease (50 trials, 20 publications) — already have substantial existing clinical evidence and may be more productive candidates to prioritise ahead of this one
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.